Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure

Nephrology Dialysis Transplantation

Volumn 14, Issue 5, 1999, Pages 1171-1175

  Aucella, Filippo ^a   Vigilante, Mimmo ^a   Scalzulli, Potito ^a   Musto, Pellegrino ^a   Prencipe, Michele ^a   Valente, Giuseppe Lucio ^a   Carotenuto, Mario ^a   Stallone, Carmine ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Chronic uraemia; Desferrioxamine; Erythroid precursors; Erythropoiesis

Indexed keywords

ALUMINUM; DEFEROXAMINE; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ADULT; AGED; ARTICLE; BURST FORMING UNIT E; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; DRUG POTENTIATION; ERYTHROCYTE; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; RETICULOCYTE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; COLONY-FORMING UNITS ASSAY; DEFEROXAMINE; DRUG SYNERGISM; ERYTHROID PROGENITOR CELLS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 0032921995     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.5.1171     Document Type: Article

References (28)

1. Casati S, Castelnuovo C, Campise M, Ponticelli C. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5: 441-443
2. Altman P. Aluminium toxicity in dialysis patients: no evidence for a threshold serum aluminium concentration. Nephrol Dial Transplant 1993; 8 [Suppl 1]: 25-34
3. Praga M, Andres M et al. Improvement of anaemia with desferoxamine in haemodialysis patients. Nephrol Dial Transplant 1987; 2: 243-247
4. Romero R, Novoa D et al. Direct effect of desferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin. Nephron 1993; 63: 164-167
5. Giordano N, Fioravanti A et al. Increased storage of iron and anemia in rheumatoid arthritis: usefulness of desferoxamine. Br Med J 1984; 289: 961-962
6. Ekert H, Rawlinson I. Desferoxamine and favism. N Engl J Med 1985; 312: 1260
7. Jensen PD, Heickendorff L et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299
8. De La Serna J, Praga M, Gilsanz F, Rodicio J et al. Improvement in the erythropoiesis of chronic hemodialysis patients with desferrioxamine. Lancet 1988; 1: 1009-1011
9. Drucke T, Basile C. Desferioxamine, anemia and hemodialysis. Lancet 1988; 1: 1405-1406
10. Basile C, Scatizzi A. Desferrioxamine does not improve aluminium-unrelated anaemia of haemodialysis. Nephrol Dial Transplant 1988; 3: 355
11. Salvarani C, Baricchi R, Lasagni D et al. Effects of desferrioxamine therapy on chronic disease anemia associated with rheumatoid arthritis. Rheumatol Int 1996; 16: 45-48
12. Smeets M, Vreugdenhil S, Holdrinet R. Improvement of erythropoiesis during treatment with defiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996; 51: 243-244
13. El-Reshaid K, Johny KV, Hakim A, et al. Erythropoietin treatment in haemodialysis patients with iron overload. Acta Haematol 1994; 91: 130-135
14. Vreugdenhil G, Smeets M, Feelders RA, Van Eijk HG. Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron loading anaemia. Acta Hematol 1993; 89: 57-60
15. Sawyer ST, Krantz SB. Transferrin receptor number, synthesis and endocytosis during erythropoietin induced maturation of Friend virus infected erythroid cells. J Biol Chem 1988; 261: 9187-9195
16. Vreugdenhil G, Feelders RA, Coppens PJW, de Leeuw PW. Possible mechanisms underlying potentiating effects of iron chelators in hematopoietic response to erythropoietin. Nephron 1992; 61: 475-476
17. Aucella F, Vigilante M, Scalzulli P, et al. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1194-1199
18. Aucella F, Vigilante M, Piemontese M et al. Synergy of r-HuEpo and desferoxamine (DFO) on erythroid precursors proliferation in dialysis. Nephrol Dial Transplant 1997; 3: A191
19. De Broe ME, D'Haese PC et al. New insight and strategies in the diagnosis and treatment of aluminium overload in dialysis patients. Nephrol Dial Transplant 1993; 8 [Suppl 1]: 47-50
20. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose response curves for three classes of erythroid progenitors in normal human marrow and in patients with polycythemia vera. Blood 1978; 52: 1196-1210
21. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 binding activity: implications for model of hypoxia signal transduction. Blood 1993; 82: 3610-3615
22. Editorial. Metal chelation therapy, oxygen radicals and human disease. Lancet 1985; 1: 143-145
23. Louache F, Testa U, Pelici P, et al. regulation of transferrin receptors in human hemopoietic cell lines. J Biol Chem 1984; 2259: 11576-11582
24. Means RT, Krants SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1994; 7: 1639-1647
25. Khan S, O'Brian PJ. Modulating hypoxia-induced hepatocyte injury by affecting intracellular redox state. Biochim Biophys Acta 1995; 1269: 153-161
26. Fandrey J, Frede S, Ehleben W, et al. Cobalt chloride and desferrioxamine antagonize the inhibition of erythropoietin production by reactive oxygen species. Kidney Int 1997; 51: 492-496
27. Jelkman W, Pagel H, Hellwig T, Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 1997; 51: 497-501
28. Norris KC, Goodman WG, Howard N et al. Iliac crest bone biopsy for diagnosis of Al toxicity and a guide to the use of deferoxamine. Semin Nephrol 1986; 6 [Suppl 1]: 27-34